185 related articles for article (PubMed ID: 35193941)
1. Stereotactic body radiotherapy in oligometastatic cervical cancer (MITO-RT2/RAD study): a collaboration of MITO, AIRO GYN, and MaNGO groups.
Macchia G; Nardangeli A; Laliscia C; Fodor A; Draghini L; Gentile PC; D'Agostino GR; Balcet V; Bonome P; Ferioli M; Autorino R; Vicenzi L; Raguso A; Borghesi S; Ippolito E; Di Cataldo V; Cilla S; Perrucci E; Campitelli M; Gambacorta MA; Deodato F; Scambia G; Ferrandina G
Int J Gynecol Cancer; 2022 Jun; 32(6):732-739. PubMed ID: 35193941
[TBL] [Abstract][Full Text] [Related]
2. A Large, Multicenter, Retrospective Study on Efficacy and Safety of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Ovarian Cancer (MITO RT1 Study): A Collaboration of MITO, AIRO GYN, and MaNGO Groups.
Macchia G; Lazzari R; Colombo N; Laliscia C; Capelli G; D'Agostino GR; Deodato F; Maranzano E; Ippolito E; Ronchi S; Paiar F; Scorsetti M; Cilla S; Ingargiola R; Huscher A; Cerrotta AM; Fodor A; Vicenzi L; Russo D; Borghesi S; Perrucci E; Pignata S; Aristei C; Morganti AG; Scambia G; Valentini V; Jereczek-Fossa BA; Ferrandina G
Oncologist; 2020 Feb; 25(2):e311-e320. PubMed ID: 32043791
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Stereotactic Body Radiation Therapy in Oligometastatic Uterine Cancer (MITO-RT2/RAD): A Large, Real-World Study in Collaboration With Italian Association of Radiation Oncology, Multicenter Italian Trials in Ovarian Cancer, and Mario Negri Gynecologic Oncology Group Groups.
Macchia G; Pezzulla D; Campitelli M; Laliscia C; Fodor A; Bonome P; Draghini L; Ippolito E; De Sanctis V; Ferioli M; Titone F; Balcet V; Di Cataldo V; Russo D; Vicenzi L; Cossa S; Lucci S; Cilla S; Deodato F; Gambacorta MA; Scambia G; Morganti AG; Ferrandina G
Int J Radiat Oncol Biol Phys; 2023 Oct; 117(2):321-332. PubMed ID: 37150261
[TBL] [Abstract][Full Text] [Related]
4. Stereotactic radiotherapy in patients with oligometastatic or oligoprogressive gynecological malignancies: a multi-institutional analysis.
Onal C; Gultekin M; Oymak E; Guler OC; Yilmaz MT; Yuce Sari S; Akkus Yildirim B; Yildiz F
Int J Gynecol Cancer; 2020 Jun; 30(6):865-872. PubMed ID: 32273293
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of stereotactic body radiotherapy (SBRT) in oligometastatic/persistent/recurrent ovarian cancer: a prospective, multicenter phase II study (MITO-RT3/RAD).
Macchia G; Jereczek-Fossa BA; Lazzari R; Cerrotta A; Deodato F; Ippolito E; Aristei C; Gambacorta MA; Scambia G; Valentini V; Ferrandina G
Int J Gynecol Cancer; 2022 Jul; 32(7):939-943. PubMed ID: 34155084
[TBL] [Abstract][Full Text] [Related]
6. Stereotactic Body Radiotherapy for Recurrent or Oligometastatic Uterine Cervix Cancer: A Cooperative Study of the Korean Radiation Oncology Group (KROG 14-11).
Park HJ; Chang AR; Seo Y; Cho CK; Jang WI; Kim MS; Choi C
Anticancer Res; 2015 Sep; 35(9):5103-10. PubMed ID: 26254414
[TBL] [Abstract][Full Text] [Related]
7. Linac-based stereotactic body radiotherapy for oligometastatic patients with single abdominal lymph node recurrent cancer.
Jereczek-Fossa BA; Piperno G; Ronchi S; Catalano G; Fodor C; Cambria R; Fossati Ing P; Gherardi F; Alterio D; Zerini D; Garibaldi C; Baroni G; De Cobelli O; Orecchia R
Am J Clin Oncol; 2014 Jun; 37(3):227-33. PubMed ID: 22992626
[TBL] [Abstract][Full Text] [Related]
8. Stereotactic Ablative Body Radiotherapy (SABR) in Pulmonary Oligometastatic/Oligorecurrent Non-small Cell Lung Cancer Patients: A New Therapeutic Approach.
Agolli L; Valeriani M; Nicosia L; Bracci S; De Sanctis V; Minniti G; Enrici RM; Osti MF
Anticancer Res; 2015 Nov; 35(11):6239-45. PubMed ID: 26504057
[TBL] [Abstract][Full Text] [Related]
9. Radiotherapy for the treatment of distant nodes metastases from oligometastatic urothelial cancer: A retrospective case series.
Leonetti A; D'Abbiero N; Baldari G; Andreani S; Ruffini L; Viansone AA; Buti S
Int J Urol; 2018 Oct; 25(10):879-886. PubMed ID: 30103254
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of stereotactic body radiotherapy to primary tumor and metastatic locations in oligometastatic nonsmall-cell lung cancer patients.
Collen C; Christian N; Schallier D; Meysman M; Duchateau M; Storme G; De Ridder M
Ann Oncol; 2014 Oct; 25(10):1954-1959. PubMed ID: 25114022
[TBL] [Abstract][Full Text] [Related]
11. Stereotactic body radiotherapy for mediastinal lymph node with CyberKnife®: Efficacy and toxicity.
Camps-Malea A; Pointreau Y; Chapet S; Calais G; Barillot I
Cancer Radiother; 2023 May; 27(3):225-232. PubMed ID: 37080855
[TBL] [Abstract][Full Text] [Related]
12. Stereotactic body radiation therapy (SBRT) in recurrent, persistent or oligometastatic gynecological cancers.
Reshko LB; Baliga S; Crandley EF; Harry Lomas IV; Richardson MK; Spencer K; Bennion N; Mikdachi HE; Irvin W; Kersh CR
Gynecol Oncol; 2020 Dec; 159(3):611-617. PubMed ID: 33059914
[TBL] [Abstract][Full Text] [Related]
13. Volumetric intensity modulated arc therapy for stereotactic body radiosurgery in oligometastatic breast and gynecological cancers: feasibility and clinical results.
Macchia G; Deodato F; Cilla S; Torre G; Corrado G; Legge F; Gambacorta MA; Tagliaferri L; Mignogna S; Scambia G; Valentini V; Morganti AG; Ferrandina G
Oncol Rep; 2014 Nov; 32(5):2237-43. PubMed ID: 25175950
[TBL] [Abstract][Full Text] [Related]
14. Stereotactic body radiotherapy in the management of oligometastatic and recurrent biliary tract cancer: single-institution analysis of outcome and toxicity.
Franzese C; Bonu ML; Comito T; Clerici E; Loi M; Navarria P; Franceschini D; Pressiani T; Rimassa L; Scorsetti M
J Cancer Res Clin Oncol; 2020 Sep; 146(9):2289-2297. PubMed ID: 32524292
[TBL] [Abstract][Full Text] [Related]
15. Robotic image-guided stereotactic radiotherapy, for isolated recurrent primary, lymph node or metastatic prostate cancer.
Jereczek-Fossa BA; Beltramo G; Fariselli L; Fodor C; Santoro L; Vavassori A; Zerini D; Gherardi F; Ascione C; Bossi-Zanetti I; Mauro R; Bregantin A; Bianchi LC; De Cobelli O; Orecchia R
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):889-97. PubMed ID: 21277113
[TBL] [Abstract][Full Text] [Related]
16. Stereotactic radiotherapy in oligoprogressive and oligorecurrent urothelial cancer patients: A retrospective experience.
Francolini G; Desideri I; Detti B; Di Cataldo V; Masi L; Caramia G; Visani L; Terziani F; Muntoni C; Lo Russo M; Loi M; Livi L
Cancer Treat Res Commun; 2019; 19():100124. PubMed ID: 30851645
[TBL] [Abstract][Full Text] [Related]
17. Stereotactic body radiation therapy for oligometastatic pulmonary tumors from cervical cancer.
Hou X; Wang W; Zhang F; Hu K
Asia Pac J Clin Oncol; 2019 Oct; 15(5):e175-e180. PubMed ID: 31070018
[TBL] [Abstract][Full Text] [Related]
18. Stereotactic Body Radiation Therapy for Oligometastatic Ovarian Cancer: A Step Toward a Drug Holiday.
Lazzari R; Ronchi S; Gandini S; Surgo A; Volpe S; Piperno G; Comi S; Pansini F; Fodor C; Orecchia R; Tomao F; Parma G; Colombo N; Jereczek-Fossa BA
Int J Radiat Oncol Biol Phys; 2018 Jul; 101(3):650-660. PubMed ID: 29893277
[TBL] [Abstract][Full Text] [Related]
19. Stereotactic ablative radiation therapy for oligometastatic renal cell carcinoma (SABR ORCA): a meta-analysis of 28 studies.
Zaorsky NG; Lehrer EJ; Kothari G; Louie AV; Siva S
Eur Urol Oncol; 2019 Sep; 2(5):515-523. PubMed ID: 31302061
[TBL] [Abstract][Full Text] [Related]
20. Stereotactic Body Radiotherapy of Lymph Node Oligometastases.
Burkoň P; Oberreiterová S; Kazda T; Slávik M; Bobek L; Komínek L; Procházka T; Vrzal M; Šlampa P
Klin Onkol; 2020; 33(2):114-122. PubMed ID: 32303132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
